Why the study?
Do mTOR and S6K1 inhibitors reduce platelet activation and aggregation?
Population
Platelets (preclinical model)
Design
Preclinical
Authors
Loading...
mTOR/S6K1 inhibition attenuates platelet activation in animal models; leaves open translation to human antithrombotic therapy.
Do mTOR and S6K1 inhibitors reduce platelet activation and aggregation?
This study identifies a novel mechanistic role for the mTOR/S6K1 pathway in regulating Rac1-driven platelet activation and thrombus formation, providing insights into the pharmacology of the mTOR system.
Aslan et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: